A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Launched by BOEHRINGER INGELHEIM · Apr 11, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether a medication called vicadrostat, when combined with another medicine called empagliflozin, can help improve kidney function in adults with chronic kidney disease (CKD) who are at risk of their condition getting worse. The study will involve adults aged 18 and older who have certain kidney function measurements and are currently stable on specific blood pressure medications. However, people who have taken certain other kidney medications recently or have specific health conditions will not be able to participate.

Participants in the trial will be randomly divided into two groups. One group will take both study medications daily for three months, while the other group will start with a placebo (a non-active tablet) and empagliflozin for the first 1.5 months before switching to the combination of both medications for the next 1.5 months. Throughout the four-month study, participants will visit the study site regularly for health check-ups and tests to monitor their kidney function. This study aims to see if the timing of starting the medications makes a difference in how well they work.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At least 18 years old and at least of the legal age of consent in countries where it is greater than 18 years.
• • 2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
• • 3. Male or female participants. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. For men, birth control is not required during the trial. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
• • 4. Evidence of Chronic Kidney Disease (CKD) at risk of progression based on two Estimated Glomerular Filtration Rate (eGFR) measurements recorded recently (i.e. within 1 year) and at the time of Visit 1, with each Estimated Glomerular Filtration Rate (eGFR) ≥20 and \<60 mL/min/1.73m2, irrespective of urine albumin creatinine ratio (UACR). The first of these measurements will be In Approval assessed from historical local laboratory results, and the second will be determined from serum creatinine analysed by the central laboratory at Visit 1.
• • 5. Treatment with a clinically appropriate, stable dose of either Angiotensin-converting enzyme inhibitor (ACEi) or Angiotensin II Receptor Blockers (ARB) (but not both together) for ≥4 weeks before Visit 1, with no planned changes of the therapy for the duration of the trial.
• Exclusion Criteria:
• • 1. Treatment with an SGLT2i within 4 weeks before Visit 2. Treatment with a sodium glucose co transporter 2 inhibitor (SGLT2i) should not be interrupted with the intention of enrolment into the trial.
• • 2. Treatment with an mineralocorticoid receptor antagonist (MRA), aldosterone synthase inhibitor (ASi), or potassium-sparing diuretic(s) within 14 days prior to Visit 1, or requiring such treatment before randomisation, or planned during the trial, based on the judgment of the investigator. Treatment with an MRA or ASi should not be interrupted with the intention of enrolment into the trial.
• • 3. Blood potassium of \>5.2 mmol/L at Visit 1.
• • 4. Blood Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>3x Upper limit of normal (ULN) at Visit 1.
• • 5. Known severe hepatic impairment (i.e. Child Pugh class C cirrhosis).
• • 6. On dialysis, functioning kidney transplant, or scheduled for transplant.
• • 7. Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days.
• • 8. Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone).
• • Further exclusion criteria apply.